Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
出版年份 2018 全文链接
标题
Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
作者
关键词
Type 2 diabetes, HbA1c, Glucagon-like peptide-1 receptor agonists, Exenatide, Liraglutide, Lixisenatide, Albiglutide, Dulaglutide, Semaglutide, Cardiovascular risk factors, Cardiovascular outcomes
出版物
Current Diabetes Reports
Volume 18, Issue 10, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-08-31
DOI
10.1007/s11892-018-1043-z
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials
- (2018) Xiaoming Jia et al. CARDIOVASCULAR DRUGS AND THERAPY
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
- (2018) M Angelyn Bethel et al. Lancet Diabetes & Endocrinology
- A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data
- (2017) Evgenia Gourgari et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
- (2017) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- 9. Cardiovascular Disease and Risk Management
- (2016) DIABETES CARE
- 4. Lifestyle Management
- (2016) DIABETES CARE
- Carotid Intima-Media Thickness for Atherosclerosis
- (2016) Tomohisa Nezu et al. Journal of Atherosclerosis and Thrombosis
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus
- (2016) Jean-Luc Faillie et al. JAMA Internal Medicine
- Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
- (2015) Wei Ren Chen et al. AMERICAN HEART JOURNAL
- Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
- (2015) Sten Madsbad DIABETES OBESITY & METABOLISM
- Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention
- (2015) Tsuyoshi Nozue et al. HEART AND VESSELS
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study
- (2014) Manfredi Rizzo et al. Cardiovascular Diabetology
- Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers
- (2014) Eren Gurkan et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: A prospective study
- (2014) Gonzalo Díaz-Soto et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials
- (2014) Vivian A. Fonseca et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
- (2014) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- Cardioprotective Effects of Exenatide in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
- (2013) Jong Shin Woo et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
- (2013) J. Rosenstock et al. DIABETES CARE
- Is Glucose Control Important for Prevention of Cardiovascular Disease in Diabetes?
- (2013) E. Mannucci et al. DIABETES CARE
- Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials
- (2013) B. Wang et al. DIABETES OBESITY & METABOLISM
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia
- (2012) Jacob Lønborg et al. Circulation-Cardiovascular Interventions
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus
- (2012) Linong Ji et al. Journal of Diabetes Investigation
- EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)
- (2011) William B. White et al. AMERICAN HEART JOURNAL
- The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus
- (2011) Marshall Elam et al. Clinical Lipidology
- Therapy in the Early Stage: Incretins
- (2011) S. Cernea et al. DIABETES CARE
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
- (2011) Jacob Lønborg et al. EUROPEAN HEART JOURNAL
- Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease
- (2011) Philip A Read et al. HEART
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
- (2011) Thomas Blevins et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection
- (2011) Amanda N. Long et al. Journal of Clinical Hypertension
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of flow-mediated dilation in humans: a methodological and physiological guideline
- (2010) Dick H. J. Thijssen et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition
- (2010) M. C. Bunck et al. DIABETES CARE
- Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents
- (2010) J. B. Buse et al. DIABETES CARE
- DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
- (2010) J. B. Buse et al. DIABETES CARE
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)
- (2008) Robert Wilcox et al. AMERICAN HEART JOURNAL
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
- (2008) J.-P. Courrèges et al. DIABETIC MEDICINE
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search